VarmX (www.varmx.com) is a young Leiden based biotech company that is focusing on the development of therapies in the field of hemostasis and thrombosis. Originally a spin-off from the Leiden University Medical Center (LUMC), our mission is to develop and manufacture therapeutic proteins to restore hemostasis. Our lead compound, VMX-C001, is intended to safely and effectively restore hemostasis in case of bleeding or emergency surgery in patients taking so-called oral factor Xa inhibitors. The VarmX program has gained significant interest in the investment community and a very successful Series B financing round of €32 mill. was closed in 2020. This round was followed by a Series B2 round of €32 mill. in May 2023 allowing the company to further progress the lead program towards Investigational New Drug (IND) approval and prepare for pivotal trials.
Externe link voor VarmX
Middelweg 38B
Leiden, 2312 KJ, NL
Automatikvej 1
Søborg, Capital Region 2860, DK
VarmX heeft dit gerepost
Very excited to attend the Wuxi Global forum during JPM.
John Glasspool, Martijn Negen MSc MBA and Paul Roos are thrilled to be hosting an Executive Roundtable at WuXi AppTec's #WuXiGlobalForum event alongside #JPM2025. Excited to share VarmX’s knowledge on transforming the treatment of coagulation factor disorders that cause bleeding or thrombosis. Every innovation story matters. https://lnkd.in/eJ5m3X_j
VarmX heeft dit gerepost
Very excited to attend the Wuxi Global forum during JPM.
John Glasspool, Martijn Negen MSc MBA and Paul Roos are thrilled to be hosting an Executive Roundtable at WuXi AppTec's #WuXiGlobalForum event alongside #JPM2025. Excited to share VarmX’s knowledge on transforming the treatment of coagulation factor disorders that cause bleeding or thrombosis. Every innovation story matters. https://lnkd.in/eJ5m3X_j
John Glasspool, Martijn Negen MSc MBA and Paul Roos are thrilled to be hosting an Executive Roundtable at WuXi AppTec's #WuXiGlobalForum event alongside #JPM2025. Excited to share VarmX’s knowledge on transforming the treatment of coagulation factor disorders that cause bleeding or thrombosis. Every innovation story matters. https://lnkd.in/eJ5m3X_j
2025 kicks off with J.P. Morgan week in San Francisco – the VarmX team looks forward to seeing you there!
The VarmX team - CEO John Glasspool, COO Martijn Negen MSc MBA and CFO Paul Roos - will be in San Francisco for the Annual J.P. Morgan Healthcare Conference week from 13-16 January 2025 to engage with potential investors as part of the ongoing Series C financing round. We’re also keen to connect with potential partners around co-development opportunities in Japan for our lead asset VMX-C001, a factor Xa DOAC bypassing agent. If you’d like to meet with us, get in touch – info@varmx.com. #JPM2025 #innovation #investment #partnering
The VarmX team - CEO John Glasspool, COO Martijn Negen MSc MBA and CFO Paul Roos - will be in San Francisco for the Annual J.P. Morgan Healthcare Conference week from 13-16 January 2025 to engage with potential investors as part of the ongoing Series C financing round. We’re also keen to connect with potential partners around co-development opportunities in Japan for our lead asset VMX-C001, a factor Xa DOAC bypassing agent. If you’d like to meet with us, get in touch – info@varmx.com. #JPM2025 #innovation #investment #partnering
The VarmX team will be presenting at the American Society of Hematology (ASH) Annual Meeting and Exposition taking place in San Diego from 7-10 December. 💡Director of Research Daniel Verhoef will be speaking on Paradigm Shifts in the Reversal of DOACs on 8 December at 4.30pm Room 28 A-D 💡Daniel Verhoef will also present a poster titled Vmx-C001 Prevents Rivaroxaban-Induced Bleeding in a Liver Injury Model in Cynomolgus Monkeys, on 7 December from 5.30pm in Halls G-H 💡CMO Gerard Short will present a poster titled Phase 1 Study of the Safety and Pharmacodynamics of a Single Dose of Vmx-C001 in Healthy Subjects with and without FXa Direct Oral Anticoagulants on 8 December at 6:00pm in Halls G-H
VarmX heeft dit gerepost
📢 Physician to Join VarmX as Clinical Development Lead! VarmX is dedicated to revolutionizing the treatment of severe bleeding with our innovative medicine, VMX-C001. As we progress into global Phase 2 and Phase 3 studies, we are searching for an experienced industry physician to become Clinical Development Lead and take on a pivotal role in shaping the future of life-saving treatments. Why Join Us? ✅ Be part of a small, collaborative, and high-performing team. ✅ Lead the clinical development of VMX-C001. ✅ Work remotely with no requirement to relocate to our Leiden office. ✅ Make a tangible impact by advancing life-changing therapies. About the Role: As the Clinical Development Lead, you will: • Report directly to the Chief Medical Officer. • Refine and lead the clinical development strategy for VMX-C001. • Oversee large, complex global Phase 2 and Phase 3 trials in emergency patient settings. • Build and manage a clinical team of experts and contractors. • Collaborate with cross-functional teams (e.g., clinical operations, regulatory affairs, and business development). • Ensure scientific rigor and operational excellence in clinical trials from start to finish. This is a highly visible leadership role requiring both strategic foresight and hands-on involvement in delivering results. Who Should Apply? We are seeking a candidate with: • Medical degree • Proven experience in clinical development, especially in late-phase trials (Phases 2/3). • Expertise in managing complex, global studies in acute/emergency patient care. • Strong leadership skills with the ability to build and manage clinical teams. • A deep understanding of regulatory and operational requirements for clinical studies. • Experience in collaborating with CROs and external experts. • A track record of delivering clinical strategies successfully. Preferred: Experience with innovative study designs (e.g., seamless Phase 2/3, basket, or umbrella trials). How to Apply: If you’re ready to bring your expertise to a groundbreaking organization and help revolutionize the treatment of severe bleeding, we’d love to hear from you! ➡️ Apply by sending your CV and cover letter to careers@varmx.com. Note: We only accept applications from individuals and are not engaging with nor reaching out to agencies. Join us on this exciting journey—let’s transform the future of healthcare together! #Hiring #Biotech #ClinicalDevelopmentLead #VarmX #MedicalLeadership
📢 Physician to Join VarmX as Clinical Development Lead! VarmX is dedicated to revolutionizing the treatment of severe bleeding with our innovative medicine, VMX-C001. As we progress into global Phase 2 and Phase 3 studies, we are searching for an experienced industry physician to become Clinical Development Lead and take on a pivotal role in shaping the future of life-saving treatments. Why Join Us? ✅ Be part of a small, collaborative, and high-performing team. ✅ Lead the clinical development of VMX-C001. ✅ Work remotely with no requirement to relocate to our Leiden office. ✅ Make a tangible impact by advancing life-changing therapies. About the Role: As the Clinical Development Lead, you will: • Report directly to the Chief Medical Officer. • Refine and lead the clinical development strategy for VMX-C001. • Oversee large, complex global Phase 2 and Phase 3 trials in emergency patient settings. • Build and manage a clinical team of experts and contractors. • Collaborate with cross-functional teams (e.g., clinical operations, regulatory affairs, and business development). • Ensure scientific rigor and operational excellence in clinical trials from start to finish. This is a highly visible leadership role requiring both strategic foresight and hands-on involvement in delivering results. Who Should Apply? We are seeking a candidate with: • Medical degree • Proven experience in clinical development, especially in late-phase trials (Phases 2/3). • Expertise in managing complex, global studies in acute/emergency patient care. • Strong leadership skills with the ability to build and manage clinical teams. • A deep understanding of regulatory and operational requirements for clinical studies. • Experience in collaborating with CROs and external experts. • A track record of delivering clinical strategies successfully. Preferred: Experience with innovative study designs (e.g., seamless Phase 2/3, basket, or umbrella trials). How to Apply: If you’re ready to bring your expertise to a groundbreaking organization and help revolutionize the treatment of severe bleeding, we’d love to hear from you! ➡️ Apply by sending your CV and cover letter to careers@varmx.com. Note: We only accept applications from individuals and are not engaging with nor reaching out to agencies. Join us on this exciting journey—let’s transform the future of healthcare together! #Hiring #Biotech #ClinicalDevelopmentLead #VarmX #MedicalLeadership
The VarmX team will be attending the Jefferies London Healthcare conference next week. CEO John Glasspool, CFO Paul Roos and COO Martijn Negen MSc MBA will be attending from 19-21 November. Looking forward to seeing you there. If you’d like to meet, just get in touch. #JefferiesHealthcare #investment #innovation #growth
Our CEO John Glasspool and COO Martijn Negen MSc MBA will be presenting at this year’s Investival Showcase in London on 18 November. Looking forward to seeing you there. If you’d like to meet, just get in touch. #Investival #investment #innovation #growth